SG176962A1 - A method and system for the detection of cancer - Google Patents

A method and system for the detection of cancer Download PDF

Info

Publication number
SG176962A1
SG176962A1 SG2011095403A SG2011095403A SG176962A1 SG 176962 A1 SG176962 A1 SG 176962A1 SG 2011095403 A SG2011095403 A SG 2011095403A SG 2011095403 A SG2011095403 A SG 2011095403A SG 176962 A1 SG176962 A1 SG 176962A1
Authority
SG
Singapore
Prior art keywords
antigen
antigens
cancer
sample
relative contribution
Prior art date
Application number
SG2011095403A
Other languages
English (en)
Inventor
Galit Yahalom
Alon Hayka
Original Assignee
Eventus Diagnostics Israel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eventus Diagnostics Israel Ltd filed Critical Eventus Diagnostics Israel Ltd
Publication of SG176962A1 publication Critical patent/SG176962A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Pure & Applied Mathematics (AREA)
  • Mathematical Physics (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Analysis (AREA)
  • Computational Mathematics (AREA)
  • Databases & Information Systems (AREA)
  • Software Systems (AREA)
  • General Engineering & Computer Science (AREA)
SG2011095403A 2009-06-23 2010-06-23 A method and system for the detection of cancer SG176962A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21953909P 2009-06-23 2009-06-23
PCT/IL2010/000498 WO2010150254A2 (en) 2009-06-23 2010-06-23 A method and system for the detection of cancer

Publications (1)

Publication Number Publication Date
SG176962A1 true SG176962A1 (en) 2012-01-30

Family

ID=42710569

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011095403A SG176962A1 (en) 2009-06-23 2010-06-23 A method and system for the detection of cancer

Country Status (7)

Country Link
US (1) US20120202226A1 (enExample)
EP (1) EP2446272A2 (enExample)
JP (1) JP2012531581A (enExample)
KR (1) KR20120098992A (enExample)
AU (1) AU2010264067A1 (enExample)
SG (1) SG176962A1 (enExample)
WO (1) WO2010150254A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE50076E1 (en) 2015-12-30 2024-08-13 Hyundai Heavy Industries Co., Ltd. Liquefied gas carrier
US11544582B2 (en) * 2016-02-02 2023-01-03 Ambertag, Inc. Predictive modelling to score customer leads using data analytics using an end-to-end automated, sampled approach with iterative local and global optimization
CN108780092A (zh) 2016-03-07 2018-11-09 豪夫迈·罗氏有限公司 抗p53抗体的检测
JP7128196B2 (ja) 2017-03-01 2022-08-30 エフ．ホフマン－ラ ロシュ アーゲー 検体の存在に関する生体サンプルの分類のためのシステムおよび方法
KR102007664B1 (ko) * 2017-07-17 2019-08-07 김준 암 진단기 및 이를 이용한 암 진단시스템
US11804298B2 (en) 2017-07-17 2023-10-31 Joon Kim Cancer diagnostic apparatus and cancer diagnostic system using the same
ES2876038T3 (es) 2018-02-18 2021-11-11 Marquez Marquez Lidia Método, aparato y kit para la detección temprana de cáncer de mama
JP7157941B2 (ja) * 2020-08-05 2022-10-21 憲一 佐藤 癌罹患判定方法、装置、およびプログラム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
WO2000061636A2 (en) * 1999-04-14 2000-10-19 Research Corporation Technologies, Inc. Aberrantly glycosylated antibodies as marker for cancer
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
EP1367395A1 (de) * 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
MX2008016352A (es) 2006-07-08 2009-04-17 Univ Kentucky Res Found Analisis diagnostico para cancer de pulmon.
CN101632020B (zh) * 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
AU2007297310B2 (en) 2006-09-13 2013-11-07 Oncimmune Limited Improved immunoassay methods
WO2009074276A2 (en) * 2007-12-10 2009-06-18 Roche Diagnostics Gmbh Marker panel for colorectal cancer

Also Published As

Publication number Publication date
AU2010264067A2 (en) 2012-08-30
EP2446272A2 (en) 2012-05-02
WO2010150254A3 (en) 2011-10-06
WO2010150254A2 (en) 2010-12-29
US20120202226A1 (en) 2012-08-09
AU2010264067A1 (en) 2012-01-19
KR20120098992A (ko) 2012-09-06
JP2012531581A (ja) 2012-12-10

Similar Documents

Publication Publication Date Title
SG176962A1 (en) A method and system for the detection of cancer
JP6374070B2 (ja) 被験体の肺がん診断のための複合バイオマーカー群、これを利用する肺がん診断用キット、複合バイオマーカー群の情報を利用する方法およびこれを実行するコンピューティングシステム
JP6026422B2 (ja) 肺がん試験
CN108107218B (zh) 抗体测定
WO2006091734A9 (en) Compositions and methods for classifying biological samples
US20140066329A1 (en) Lung cancer diagnostic assay
CN112272773A (zh) 用于检测花生过敏的肽和方法
CN101490550A (zh) 肺癌诊断分析
EP3899541B1 (en) Lung cancer protein epitomic biomarkers
CN115877006B (zh) 卵巢癌相关的生物标志物及其应用
KR100980031B1 (ko) 대장암 진단 및 스크리닝용 단백질 마커 및 대장암 진단을 위한 상기 마커의 측정방법
JP7744641B2 (ja) 肺癌における自己抗体を検出するための抗原の組合せの使用
Liu et al. Using SELDI‐TOF MS to identify serum biomarkers of rheumatoid arthritis
WO2013166480A1 (en) Detectors of serum biomarkers for predicting ovarian cancer recurrence
US20240118282A1 (en) Kits and methods for detecting markers and determining the presence or risk of cancer
CN113933509A (zh) 抗体测定
GB2600701A (en) Antibody assay
TW201928351A (zh) 抗體測定